Lunai Bioworks
LNAI
41 hedge funds and large institutions have $19.2M invested in Lunai Bioworks in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 10 closing their positions.
217% more call options, than puts
Call options by funds: $133K | Put options by funds: $42K
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
135% more capital invested
Capital invested by funds: $8.16M → $19.2M (+$11M)
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
14% more funds holding
Funds holding: 36 → 41 (+5)
0.02% more ownership
Funds ownership: 0.05% → 0.06% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.9M |
| 2 |
Goldman Sachs
New York
|
+$989K |
| 3 |
Millennium Management
New York
|
+$564K |
| 4 |
Citigroup
New York
|
+$460K |
| 5 |
Man Group
London,
United Kingdom
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$234K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$150K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$118K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$81.2K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$64.7K |
LNAI Hedge Fund Activity: Q1 2024 in Review
41 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Lunai Bioworks (LNAI) for Q1 2024, worth a combined $19.2M — up 135% from $8.16M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LNAI positions and 10 closed out — a net gain of 5 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was 683 Capital Management, exiting entirely with an estimated $234K sold.
- 41 institutional investors held Lunai Bioworks (LNAI) as of Q1 2024, up from 36 in Q4 2023.
- Funds reported $19.2M of Lunai Bioworks stock for Q1 2024, up 135% quarter-over-quarter.
- 15 funds opened new Lunai Bioworks positions in Q1 2024 and 10 closed out, a net change of +5 holders.
- The largest Lunai Bioworks buyer in Q1 2024 was Vanguard Group, an estimated $11.9M added.
- The largest Lunai Bioworks seller in Q1 2024 was 683 Capital Management, an estimated $234K sold.
Based on aggregated 13F filings for Q1 2024.